Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1
Source: SeekingAlpha
2026-04-13 04:33:56 ET
More on Replimune Group
- Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
- Replimune: Multiple Shots On Goal But A High Risk Binary Approaches
- Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Replimune plans layoffs as FDA rejects cancer drug
- Replimune under pressure as FDA rejects lead asset again
Read the full article on Seeking Alpha
For further details see:
Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
